Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gypenoside XVII (Gynosaponin S) confers protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, activation of Nrf2/ARE/HO-1 and inactivation of GSK-3β pathways.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 92.00 | |
10 mg | In stock | $ 145.00 | |
25 mg | In stock | $ 261.00 | |
50 mg | In stock | $ 387.00 | |
100 mg | In stock | $ 575.00 |
Description | Gypenoside XVII (Gynosaponin S) confers protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, activation of Nrf2/ARE/HO-1 and inactivation of GSK-3β pathways. |
Source |
Synonyms | GP-17, Gynosaponin S |
Molecular Weight | 947.15 |
Formula | C48H82O18 |
CAS No. | 80321-69-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 105.6 mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Gypenoside XVII 80321-69-3 Endocrinology/Hormones Metabolism PI3K/Akt/mTOR signaling Stem Cells Endogenous Metabolite GSK-3 Estrogen Receptor/ERR inhibit GP-17 Gynosaponin S GP17 GP 17 Inhibitor inhibitor